Scientists utilized mice in which SIRT2 has been reduced or ablated to investigate the function of SIRT2 and determine whether SIRT2 loss has a beneficial impact on disease progression in the R6/2 mouse model of HD and found that SIRT2 ablation did not affect tubulin acetylation in the brain, cholesterol biosynthesis, or the progression of HD phenotypes in vivo, as assessed by a battery of physiological and behavioral tests [76]. The gene discussed is SIRT2; the disease is Huntington disease.